Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant Inc (IMVT) is a clinical-stage biopharmaceutical company pioneering FcRn inhibitor therapies for autoimmune diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory developments, and corporate milestones driving innovation in immunology.
Access authoritative information on batoclimab and IMVT-1402 clinical progress, partnership announcements, and financial disclosures. Our curated collection ensures you stay informed about key advancements in monoclonal antibody research without promotional bias.
Discover comprehensive updates including trial result analyses, FDA communications, and strategic initiatives shaping Immunovant's pipeline. The content is structured to serve both seasoned investors and those new to biopharma developments.
Bookmark this page for reliable, up-to-date information on Immunovant's scientific achievements and business trajectory. Check back regularly for verified news impacting the future of autoimmune disease treatments.
Immunovant (Nasdaq: IMVT) reported a net loss of $63.2 million, or $0.49 per share, for Q3 FY2022, compared to a loss of $41.4 million, or $0.36 per share, in Q3 FY2021. Cash reserves stood at approximately $433 million, expected to fund operations through 2025. The company initiated a Phase 3 trial for batoclimab in thyroid eye disease and a pivotal Phase 2b trial in chronic inflammatory demyelinating polyneuropathy. A Phase 1 trial for IMVT-1402 is expected to begin in early 2023. Investors anticipate multiple data readouts starting mid-2023, potentially enhancing the company’s position in autoimmune therapies.
Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company, announced that CEO Pete Salzmann, M.D., will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, at 3:55 pm Eastern Time. The webcast will be accessible through the company's Investor Relations section. Immunovant focuses on developing therapies for autoimmune diseases, particularly with FcRn inhibitor technology, addressing significant patient needs.
Immunovant, a clinical-stage biopharmaceutical company, reported key developments and financial results for Q2 fiscal 2022. The company introduced IMVT-1402, a next-generation FcRn inhibitor demonstrating promising results in IgG reduction. New programs for batoclimab targeting chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves' disease were announced, with pivotal trials expected soon. Financially, Immunovant's R&D expenses rose to $37.7 million, and the company posted a net loss of $47.9 million. With a pro forma cash balance of $476 million, the cash runway is projected to extend into H2 2025.
Immunovant, Inc. (Nasdaq: IMVT) announced an underwritten offering of 12,500,000 common stock shares priced at $6.00 each, expected to yield $75 million before expenses. This capital will help fund the development of IMVT-1402 and support a pivotal trial. The company anticipates that its current cash, combined with proceeds from this offering, will sustain operations through mid-2025. The offering will close around October 6, 2022, subject to standard conditions. SVB Securities and Truist Securities are the joint bookrunning managers.
FAQ
What is the current stock price of Immunovant (IMVT)?
What is the market cap of Immunovant (IMVT)?
